Login to Your Account



Gilead, Triangle Plan Merger: $464M Deal Pairs HIV Drugs

By Randall Osborne


Thursday, December 5, 2002
Having lost its figurative dance partner, Abbott Laboratories Inc., over the summer, Triangle Pharmaceuticals Inc. disclosed that it plans to undergo a "two-step" acquisition by Gilead Sciences Inc. in a deal valued at $464 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription